Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - cefuroximum natríum - stungulyfs-/innrennslisstofn, lausn - 750 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - cefuroximum natríum - stungulyfs-/innrennslisstofn, lausn - 1,5 g

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 40 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - hydrocortisonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 100 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - hydrocortisonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 250 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 125 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 500 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - krabbamein, lungnakrabbamein - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

pfizer europe ma eeig - crizotinib - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

novartis europharm limited - ceritinib - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - zykadia er ætlað til meðferðar hjá fullorðnum sjúklingum með lungnakrabbamein (anaplastic lymphoma kinase (alk)) sem hefur áður fengið meðferð með crizotinibi.